Skip to main content
AGEN
NASDAQ Life Sciences

Agenus的Botensilimab/Balstilimab联合治疗未达到二期胃食管癌研究的主要终点

feedReported by Reuters
Sentiment info
Negative
Importance info
9
Price
$4.648
Mkt Cap
$183.928M
52W Low
$1.6
52W High
$7.34
Market data snapshot near publication time

summarizeSummary

Agenus Inc.报告了其botensilimab、balstilimab和Agent-797联合治疗在PD-1耐药胃食管癌中的二期临床试验数据。关键的是，该研究未达到其主要终点，即客观响应率，这对于公司的药物开发管道来说是一个重大挫折。虽然数据表明了免疫重编程和持久的生存率，但未达到主要终点是投资者关注的主要因素。这一消息尤其重要，考虑到公司最近的10-K提交，该提交披露了公司继续经营的重大疑虑。错失关键临床里程碑可能会进一步加剧人们对公司财务可持续性和未来前景的担忧，可能导致股价出现显著的波动。投资者现在将关注公司对该计划的下一步行动以及对其财务跑道的任何潜在影响。SEC和Form 4、8-K、CIK相关信息将被密切关注，特别是公司的EBITDA和GAAP财务报表。

在该公告发布时，AGEN的交易价格为$4.65，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.8亿。 52周交易区间为$1.60至$7.34。 这则新闻被评估为消极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed AGEN - Latest Insights

AGEN
Apr 20, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Agenus Seeks Shareholder Approval for Significant Equity Plan Expansion and Option Repricing
Sentiment: Negative
View Wiseek Article
AGEN
Apr 17, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
9
Agenus's Botensilimab/Balstilimab Combo Fails Primary Endpoint in Phase II Gastroesophageal Cancer Study
Sentiment: Negative
View Wiseek Article
AGEN
Mar 26, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
8
Federal Court Dismisses Securities Class Action Against Agenus
Sentiment: Positive
View Wiseek Article
AGEN
Mar 26, 2026, 8:24 AM EDT
Filing Type: 8-K
Importance Score:
8
Agenus Secures Dismissal of Securities Class Action Lawsuit
Sentiment: Positive
View Wiseek Article
AGEN
Mar 16, 2026, 5:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Agenus Reports Going Concern Doubt, Major Partnership Terminations, and Critical Zydus Deal
Sentiment: Negative
View Wiseek Article
AGEN
Mar 16, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Agenus Advances Lead Immunotherapy to Global Phase 3, Secures $20M Payment, and Reports Strong 2025 Results
Sentiment: Positive
View Wiseek Article
AGEN
Mar 16, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Key Cancer Drug BOT+BAL Advances to Phase 3, Early Access Programs Generate $4.2M Revenue
Sentiment: Positive
View Wiseek Article
AGEN
Mar 10, 2026, 3:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Agenus Secures First $20M Milestone Payment from Zydus Collaboration for Drug Production
Sentiment: Positive
View Wiseek Article
AGEN
Jan 23, 2026, 8:57 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Strategic Partner Zydus Acquires 5.9% Stake in Agenus at Significant Premium
Sentiment: Positive
View Wiseek Article
AGEN
Jan 16, 2026, 8:25 AM EST
Filing Type: 8-K
Importance Score:
9
Agenus Secures $91M Capital and Strategic Manufacturing Capacity via Zydus Collaboration
Sentiment: Positive
View Wiseek Article